EUVIMEDEUVIMED entdecken
Crossref

Cost evaluation of a multimodal prehabilitation program for high-risk lung cancer surgery

Tahereh Najafi Ghezeljeh, Ah-Reum Cho, André Guigui, Lauren Douglas, Kevin Schwartzman, Agnihotram V Ramanakumar, Janius Tsang, Lorenzo Ferri, Jonathan Cools-Lartigue, Jonathan D Spicer, Sara Najmeh, Francesco Carli

The Journal of Thoracic and Cardiovascular Surgery · 2026

DOI: 10.1016/j.jtcvs.2026.02.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026. Verfasst von Tahereh Najafi Ghezeljeh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia, Centre for Outcomes Research and Evaluation, Research Institute, McGill University Health Centre, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Hospital Costs, Pneumonectomy, Preoperative Exercise. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Although multimodal prehabilitation has demonstrated clinical benefits, limited data exist on its economic impact. This study evaluated the cost impact of multimodal prehabilitation for high-risk patients scheduled for lung cancer surgery. METHODS: This cost analysis used data from a published propensity score-matched cohort study of 284 adults (142 per group) who underwent lung surgery between 2018 and 2024. All patients received usual care and enhanced recovery after surgery protocols; the intervention group also completed a multimodal prehabilitation program. A bottom-up microcosting approach-an itemized assessment of resource consumption and cost per unit consumed-and a per diem cost analysis were used to estimate 60-day postoperative hospital costs, program implementation expenses (staff salaries only), and cost savings in 2024 Canadian dollars (CAD) (1 CAD = 0.73 US dollar). RESULTS: The program implementation cost in CAD was CAD$54,979, CAD$387 per patient. Total 60-day postoperative hospital costs were CAD$2.08 million in the prehabilitation group compared to CAD$3.07 million in the control group, with mean cost reduction -CAD$1538 (95% CI, -CAD$2916 to -CAD$161) for surgical ward and -CAD$21,094 (95% CI, -CAD$37,028 to -CAD$5160) for intensive care unit care. Prehabilitation was associated with net cost savings of CAD$721,901 (CAD$5084 per patient). The main drivers of these savings were reductions in overall complications (45.1% vs 64.7%; P = .001), intensive care unit admissions (2.1% vs 8.4%; P = .031), hospital days (median, 3 vs 4 days; P = .049), and readmission rate (6.3% vs 13.3%; P = .044). CONCLUSIONS: Multimodal prehabilitation is a clinically effective and economically beneficial intervention for high-risk patients undergoing lung cancer surgery, supporting its integration into standard perioperative care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHospital CostsPneumonectomyPreoperative ExerciseHumansFemaleAgedMaleMiddle AgedCost-Benefit AnalysisCost SavingsTreatment OutcomeRisk FactorsPostoperative ComplicationsCanada

Stichwörter der Autor:innen

lung cancermicrocostingper diem costingpostoperative complicationsprehabilitationpropensity score matching

Autor:innen und Institutionen

  • Department of Anesthesia, Centre for Outcomes Research and Evaluation, Research Institute, McGill University Health Centre, Montréal, Québec, Canada.
  • Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Republic of Korea.
  • Department of Finance, McGill University Health Centre, Montréal, Québec, Canada.
  • McGill International Tuberculosis Centre, Research Institute, McGill University Health Centre, Montréal, Québec, Canada.
  • Department of Anesthesia, McGill University Health Centre, Montréal, Québec, Canada.
  • Division of Thoracic and Upper Gastrointestinal Surgery, Department of Surgery, McGill University Health Centre, Montréal, Québec, Canada.

Zitieren

APA

Najafi Ghezeljeh, T., Cho, A. R., Guigui, A., Douglas, L., Schwartzman, K., Ramanakumar, A. V., Tsang, J., Ferri, L., Cools-Lartigue, J., Spicer, J. D., Najmeh, S., & Carli, F. (2026). Cost evaluation of a multimodal prehabilitation program for high-risk lung cancer surgery. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2026.02.013

Vancouver

Najafi Ghezeljeh T, Cho AR, Guigui A, Douglas L, Schwartzman K, Ramanakumar AV, et al. Cost evaluation of a multimodal prehabilitation program for high-risk lung cancer surgery. The Journal of Thoracic and Cardiovascular Surgery. 2026. doi:10.1016/j.jtcvs.2026.02.013

BibTeX
@article{NajafiGhezeljeh2026,
  author = {Najafi Ghezeljeh, Tahereh and Cho, Ah-Reum and Guigui, André and Douglas, Lauren and Schwartzman, Kevin and Ramanakumar, Agnihotram V and Tsang, Janius and Ferri, Lorenzo and Cools-Lartigue, Jonathan and Spicer, Jonathan D and Najmeh, Sara and Carli, Francesco},
  title = {Cost evaluation of a multimodal prehabilitation program for high-risk lung cancer surgery},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  doi = {10.1016/j.jtcvs.2026.02.013}
}
Kostenlos starten →